Phoenix Life Sciences International Limited
PLSI
Other OTC0.00
USD
-0.82
- -
CIK
0001493212
CUSIP
71910Q102
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-99.97
76.60
5Y
-100.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Willis Victory
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4262 Blue Diamond Road Las Vegas NV United States of America 89139
- IPO Date
- Sep 23, 2011
- CIK
- 0001493212
- Website
- phoenixlife.co
- Similar Companies
- Business
- Phoenix Life Sciences International Limited operates as an adaptive healthcare solutions company specializing in the development, production, and distribution of plant-based pharmaceutical products. Its core offerings include plant-based medicines targeting diabetes management, pain relief, cancer treatment, autoimmune diseases, anxiety, neurological and psychological disorders, gastrointestinal issues, and sleep disorders. The company manufactures and markets a diverse portfolio of products under brand names such as Phoenix Metabolic, Phoenix Auto, Phoenix Calm, Phoenix Daytime, Phoenix Mood, Phoenix Neuro, Phoenix Onco, Phoenix Pain, Phoenix Relax, and Phoenix Sleep. In addition to its pharmaceutical products, Phoenix Life Sciences provides healthcare services focused on establishing national diabetes management programs, community healthcare clinics, and screening services primarily in developing and least developed countries. These services help governments implement affordable, fixed-price solutions for managing non-communicable diseases. Recent major company developments include the signing of an exclusive 25-year agreement with the government of Vanuatu for diabetes management and global medical programs, reinforcing its strategic focus on government healthcare partnerships. Phoenix Life Sciences also completed the acquisition of Phoenix Bio Pharmaceuticals, securing ownership of intellectual property assets related to condition-specific formulations, proprietary compounds, extraction technologies, and delivery systems for medical cannabis products. This acquisition expands the company’s IP portfolio and positions it to develop production and distribution facilities in the United States and internationally while pursuing patent filings for these innovations. Furthermore, Phoenix Life Sciences has been advancing its offering by integrating innovative technologies such as AI-driven analytics and at-home medical testing kits, empowering personalized health solutions through continuous patient monitoring. Founded in 2005 and headquartered in Denver, Colorado, Phoenix Life Sciences operates globally with a significant presence in markets including Australia, Canada, Germany, and various developing nations. The company’s industry sectors include pharmaceuticals, biotechnology, plant-based medicine, and healthcare services. It aligns its operations with government health agencies, insurers, and sponsors to deliver community-centric healthcare programs and affordable access to plant-based therapeutics, especially targeting diabetes and other chronic diseases. Phoenix Life Sciences integrates ongoing research programs with its commercial activities to support the development of novel, safe, and natural treatment options worldwide. Overall, Phoenix Life Sciences International Limited is distinguished by its combination of plant-based pharmaceutical manufacturing, government-focused healthcare service delivery, research innovation, and recent strategic expansions in IP and global program partnerships. Its comprehensive product portfolio and service platforms reflect a commitment to accessible, safe, and effective healthcare solutions in both emerging and developed markets.